JP2020532532A5 - - Google Patents

Download PDF

Info

Publication number
JP2020532532A5
JP2020532532A5 JP2020512430A JP2020512430A JP2020532532A5 JP 2020532532 A5 JP2020532532 A5 JP 2020532532A5 JP 2020512430 A JP2020512430 A JP 2020512430A JP 2020512430 A JP2020512430 A JP 2020512430A JP 2020532532 A5 JP2020532532 A5 JP 2020532532A5
Authority
JP
Japan
Prior art keywords
compound according
alkyl
aryl
independently
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020512430A
Other languages
English (en)
Japanese (ja)
Other versions
JP7270608B2 (ja
JP2020532532A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/048705 external-priority patent/WO2019046511A1/en
Publication of JP2020532532A publication Critical patent/JP2020532532A/ja
Publication of JP2020532532A5 publication Critical patent/JP2020532532A5/ja
Priority to JP2023070638A priority Critical patent/JP7673118B2/ja
Application granted granted Critical
Publication of JP7270608B2 publication Critical patent/JP7270608B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020512430A 2017-08-31 2018-08-30 化合物、組成物、及び疾患の治療方法 Active JP7270608B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023070638A JP7673118B2 (ja) 2017-08-31 2023-04-24 化合物、組成物、及び疾患の治療方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762552473P 2017-08-31 2017-08-31
US62/552,473 2017-08-31
US201862664493P 2018-04-30 2018-04-30
US62/664,493 2018-04-30
PCT/US2018/048705 WO2019046511A1 (en) 2017-08-31 2018-08-30 COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023070638A Division JP7673118B2 (ja) 2017-08-31 2023-04-24 化合物、組成物、及び疾患の治療方法

Publications (3)

Publication Number Publication Date
JP2020532532A JP2020532532A (ja) 2020-11-12
JP2020532532A5 true JP2020532532A5 (enExample) 2021-10-07
JP7270608B2 JP7270608B2 (ja) 2023-05-10

Family

ID=65526007

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020512430A Active JP7270608B2 (ja) 2017-08-31 2018-08-30 化合物、組成物、及び疾患の治療方法
JP2023070638A Active JP7673118B2 (ja) 2017-08-31 2023-04-24 化合物、組成物、及び疾患の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023070638A Active JP7673118B2 (ja) 2017-08-31 2023-04-24 化合物、組成物、及び疾患の治療方法

Country Status (6)

Country Link
US (1) US11638716B2 (enExample)
EP (1) EP3675859A4 (enExample)
JP (2) JP7270608B2 (enExample)
CA (1) CA3074232A1 (enExample)
TW (1) TWI688390B (enExample)
WO (1) WO2019046511A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3429596B1 (en) 2016-03-18 2022-08-31 Immune Sensor, LLC Cyclic di-nucleotide compounds and methods of use
WO2018156625A1 (en) 2017-02-21 2018-08-30 Board Of Regents,The University Of Texas System Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
WO2019046511A1 (en) 2017-08-31 2019-03-07 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
EP3728283B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
JP7335277B2 (ja) 2018-06-01 2023-08-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 膀胱がんの治療のための方法
US11161864B2 (en) 2018-10-29 2021-11-02 Venenum Biodesign, LLC Sting agonists
US11110106B2 (en) 2018-10-29 2021-09-07 Venenum Biodesign, LLC Sting agonists for treating bladder cancer and solid tumors
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
US11787833B2 (en) * 2019-05-09 2023-10-17 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as sting modulators
CA3145889A1 (en) 2019-07-05 2021-01-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
EP4134098A4 (en) 2020-04-10 2024-05-15 ONO Pharmaceutical Co., Ltd. Method of cancer therapy
MX2022014110A (es) 2020-05-15 2023-01-30 Immunesensor Therapeutics Inc Tratamientos combinados de agonistas de sting con inhibidores de puntos de control inmunitario.
CN116056765A (zh) 2020-08-07 2023-05-02 坦伯公司 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途
US20230121320A1 (en) 2021-07-23 2023-04-20 Immunesensor Therapeutics, Inc. Sting agonist combination treatments with cytokines
GB202304385D0 (en) 2023-03-24 2023-05-10 Prostate Cancer Res Combinatorial IL-15 therapy

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6257607B2 (ja) 2012-06-08 2018-01-10 アデュロ バイオテック,インコーポレイテッド 癌免疫療法のための組成物および方法
MX361680B (es) 2012-12-13 2018-12-13 Aduro Biotech Inc Composiciones que comprenden dinucleótidos de purina cíclicos que tienen estereoquímicas definidas y métodos para su preparación y uso.
EP2956145A4 (en) * 2013-02-18 2016-08-17 Spring Bank Pharmaceuticals Inc DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINATE ADJUVANTIES AND THERAPEUTICS
JP6400082B2 (ja) 2013-05-18 2018-10-03 アデュロ バイオテック,インコーポレイテッド 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を抑制するための組成物および方法
ES2754269T3 (es) 2013-05-18 2020-04-16 Aduro Biotech Inc Composiciones y métodos de activación de la señalización dependiente del "estimulador de los genes de interferón
US20160287623A1 (en) 2013-11-19 2016-10-06 The University Of Chicago Use of sting agonist as cancer treatment
ES3040431T3 (en) 2014-03-12 2025-10-31 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
CR20160564A (es) 2014-06-04 2017-01-20 Glaxosmithkline Ip Dev Ltd Dinucleótidos cíclicos como moduladores de sting
CH710524A2 (fr) 2014-12-18 2016-06-30 Swatch Group Res & Dev Ltd Résonateur d'horlogerie à lames croisées.
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
CA2979215A1 (en) 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
MA42608A (fr) 2015-08-13 2018-06-20 Merck Sharp & Dohme Composés de di-nucléotide cyclique en tant qu'agonistes sting (stimulateur de gène interféron)
CN108430503A (zh) 2015-10-28 2018-08-21 艾杜罗生物科技公司 用于激活“干扰素基因刺激物”依赖性信号传导的组合物和方法
CA3006930A1 (en) 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
CN106540260A (zh) 2015-12-09 2017-03-29 聊城市奥润生物医药科技有限公司 干扰素基因刺激蛋白(sting)激动剂在抗阿尔兹海默症中的应用
WO2017106740A1 (en) 2015-12-16 2017-06-22 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production
KR20250049441A (ko) 2016-01-11 2025-04-11 인네이트 튜머 이뮤니티, 인코포레이티드 Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드
WO2017123657A1 (en) 2016-01-11 2017-07-20 Gary Glick Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
AU2017225769B2 (en) 2016-03-02 2023-01-05 The Board Of Regents Of The University Of Texas System Sting activating nanovaccine for immunotherapy
EP3429596B1 (en) 2016-03-18 2022-08-31 Immune Sensor, LLC Cyclic di-nucleotide compounds and methods of use
WO2017186711A1 (en) 2016-04-25 2017-11-02 Invivogen Novel complexes of immunostimulatory compounds, and uses thereof
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018045204A1 (en) 2016-08-31 2018-03-08 Ifm Therapeutics, Inc Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
RS62410B1 (sr) 2016-10-04 2021-10-29 Merck Sharp & Dohme Benzo[b]tiofenska jedinjenja kao agonisti sting
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
AU2017378782A1 (en) 2016-12-20 2019-07-04 Merck Sharp & Dohme Corp. Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
US20200113924A1 (en) 2016-12-20 2020-04-16 Merck Sharp & Dohme Corp. Cyclic dinucleotide sting agonists for cancer treatment
WO2018156625A1 (en) 2017-02-21 2018-08-30 Board Of Regents,The University Of Texas System Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
KR20200028392A (ko) 2017-06-12 2020-03-16 유니버시티 오브 마이애미 질환의 치료를 위한 sting-의존성 활성화제
JP2020524717A (ja) 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドCuradev Pharma Limited ヒトstingの小分子調節因子
US20200172483A1 (en) 2017-06-22 2020-06-04 Curadev Pharma Limited Heterocyclic small molecule modulators of human sting
CN111132972B (zh) 2017-06-22 2024-07-12 克拉德夫制药有限公司 人sting的小分子调节剂
WO2019027857A1 (en) 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. COMBINATIONS OF PD-1 ANTAGONISTS AND STING BENZO [B] THIOPHENIC AGONISTS FOR THE TREATMENT OF CANCER
JP2020530838A (ja) 2017-08-04 2020-10-29 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. がん治療のためのベンゾ[b]チオフェンSTINGアゴニスト
WO2019035901A1 (en) 2017-08-15 2019-02-21 University Of Miami COMPOSITIONS AND METHODS FOR STING PROTEIN MODULATION
WO2019046511A1 (en) 2017-08-31 2019-03-07 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE
WO2019067468A1 (en) 2017-09-26 2019-04-04 La Jolla Institute For Allergy And Immunology MODULATION OF THE IMMUNE RESPONSE THROUGH THE STING PROTEIN
WO2019100061A1 (en) 2017-11-20 2019-05-23 Silicon Swat, Inc. Oxoacridinyl acetic acid derivatives and methods of use
WO2019104353A1 (en) 2017-11-27 2019-05-31 Children's Medical Center Corporation Stimulator of interferon genes (sting) ligands and uses thereof
WO2019125974A1 (en) 2017-12-20 2019-06-27 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
JP2021512144A (ja) 2018-01-26 2021-05-13 ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニアThe Regents of the University of California 環状ジヌクレオチドアジュバント含有結核ワクチンの鼻腔内送達
WO2019161171A1 (en) 2018-02-16 2019-08-22 Sperovie Biosciences, Inc. Nanoparticle formulations of sting agonists
JP7104999B2 (ja) 2018-02-21 2022-07-22 ザ スクリプス リサーチ インスティテュート インターフェロン遺伝子刺激因子stingのアゴニスト
US20210017541A1 (en) 2018-03-26 2021-01-21 University Of Miami Recombinant viral vector and uses thereof
WO2019195063A1 (en) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
WO2019195124A1 (en) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Benzothiophenes and related compounds as sting agonists
US20210228648A1 (en) 2018-06-04 2021-07-29 Aarhus Universitet Worm products and methods of use
EP3807264A1 (en) 2018-06-12 2021-04-21 Ryvu Therapeutics S.A. Modulators of stimulator of interferon genes (sting)
CN108498529A (zh) 2018-06-20 2018-09-07 福建师范大学 用于肿瘤预防治疗的DNA甲基转移酶抑制剂与cGAMP药物组合物
TW202016081A (zh) 2018-06-21 2020-05-01 英商克拉德夫製藥有限公司 人類sting之小分子調節劑、結合物及治療應用
WO2019243823A1 (en) 2018-06-21 2019-12-26 Curadev Pharma Limited Azaheterocyclic small molecule modulators of human sting
EP3817820A1 (en) 2018-07-03 2021-05-12 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2020010451A1 (en) 2018-07-10 2020-01-16 Trillium Therapeutics Inc. Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists
JP7468829B2 (ja) 2018-07-23 2024-04-16 フォースン オリノーヴ ファーマテック インコーポレイテッド 癌を処置するための、癌治療剤と組み合わせたIRE1α阻害剤

Similar Documents

Publication Publication Date Title
JP2020532532A5 (enExample)
JP2019532084A5 (enExample)
JP2017526677A5 (enExample)
JP2019511483A5 (enExample)
JP2019518766A5 (enExample)
JP2020507589A5 (enExample)
ES2702911T3 (es) Agente antitumoral que incluye una baja dosis de clorhidrato de irinotecán hidratado
JP2014521688A5 (enExample)
RU2015118647A (ru) Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr
JP2017531619A5 (enExample)
JP2005523922A5 (enExample)
JP2019526596A5 (enExample)
JP2013056886A5 (enExample)
JP2012519691A5 (enExample)
RU2012110007A (ru) Имидазохинолины в качестве двойных ингибиторов липидкиназы и mtor
JP2009513703A5 (enExample)
JP2021502387A5 (enExample)
JP2017515901A5 (enExample)
JP2016040288A5 (enExample)
JP2013521291A5 (enExample)
JP2017517565A5 (enExample)
JP2015500885A5 (enExample)
JP2019501879A5 (enExample)
JP2020128426A5 (enExample)
JP2014514290A5 (enExample)